Extracellular thioredoxin: A therapeutic tool to combat inflammation

Cytokine and Growth Factor Reviews

Volumn 24, Issue 4, 2013, Pages 345-353

  Matsuo, Yoshiyuki ^a,b   Yodoi, Junji ^a,b  

^a Ewha Womans University   (South Korea)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Adult T cell leukemia; Biomarker; Inflammation; Redoxisome; Thioredoxin

Indexed keywords

ADULT T CELL LEUKEMIA DERIVED FACTOR; BIOLOGICAL MARKER; CELL PROTEIN; REDOXISOME; SECRETORY PROTEIN; THIOREDOXIN; UNCLASSIFIED DRUG;

CELLULAR STRESS RESPONSE; CYTOKINE PRODUCTION; DERMATITIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SYNTHESIS; EXTRACELLULAR SPACE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; LIVER DISEASE; MIGRATION INHIBITION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SEPSIS; SHORT SURVEY; STOMACH INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT T CELL LEUKEMIA; BIOMARKER; INFLAMMATION; REDOXISOME; THIOREDOXIN;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; NEOPLASM PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84883774785     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.01.001     Document Type: Short Survey

References (100)

1. Laurent T.C., Moore E.C., Reichard P. Enzymatic synthesis of deoxyribonucleotides, IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. Journal of Biological Chemistry 1964, 239:3436-3444.
2. Holmgren A. Thioredoxin. Annual Review of Biochemistry 1985, 54:237-271.
3. Arner E.S. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biomedica Biochimica Acta 2009, 1790:495-526.
4. Rhee S.G., Chae H.Z., Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radical Biology and Medicine 2005, 38:1543-1552.
5. Lillig C.H., Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxidants and Redox Signalling 2007, 9:25-47.
6. Lee S., Kim S.M., Lee R.T. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxidants and Redox Signalling 2012, 10.1089/ars.2011.4322.
7. Masutani H., Yoshihara E., Masaki S., Chen Z., Yodoi J. Thioredoxin binding protein (TBP)-2/Txnip and alpha-arrestin proteins in cancer and diabetes mellitus. Journal of Clinical Biochemistry and Nutrition 2012, 50:23-34.
8. Chen K.S., DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biomedica Biochimica Acta 1994, 1219:26-32.
9. Nishiyama A., Matsui M., Iwata S., Hirota K., Masutani H., Nakamura H., et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. Journal of Biological Chemistry 1999, 274:21645-21650.
10. Lee K.N., Kang H.S., Jeon J.H., Kim E.M., Yoon S.R., Song H., et al. VDUP1 is required for the development of natural killer cells. Immunity 2005, 22:195-208.
11. Son A., Nakamura H., Okuyama H., Oka S., Yoshihara E., Liu W., et al. Dendritic cells derived from TBP-2-deficient mice are defective in inducing T cell responses. European Journal of Immunology 2008, 38:1358-1367.
12. Bodnar J.S., Chatterjee A., Castellani L.W., Ross D.A., Ohmen J., Cavalcoli J., et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nature Genetics 2002, 30:110-116.
13. Oka S., Liu W., Masutani H., Hirata H., Shinkai Y., Yamada S., et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB Journal 2006, 20:121-123.
14. Yoshihara E., Fujimoto S., Inagaki N., Okawa K., Masaki S., Yodoi J., et al. Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity. Nature Communications 2010, 1:127.
15. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology 2010, 11:136-140.
16. Chen Z., Lopez-Ramos D.A., Yoshihara E., Maeda Y., Masutani H., Sugie K., et al. Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation. Leukemia 2011, 25:440-448.
17. Masaki S., Masutani H., Yoshihara E., Yodoi J. Deficiency of thioredoxin binding protein-2 (TBP-2) enhances TGF-beta signaling and promotes epithelial to mesenchymal transition. PLoS ONE 2012, 7:e39900.
18. Dutta K.K., Nishinaka Y., Masutani H., Akatsuka S., Aung T.T., Shirase T., et al. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Laboratory Investigation 2005, 85:798-807.
19. Sheth S.S., Bodnar J.S., Ghazalpour A., Thipphavong C.K., Tsutsumi S., Tward A.D., et al. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 2006, 25:3528-3536.
20. Tagaya Y., Okada M., Sugie K., Kasahara T., Kondo N., Hamuro J., et al. IL-2 receptor(p55)/Tac-inducing factor. Purification and characterization of adult T cell leukemia-derived factor. Journal of Immunology 1988, 140:2614-2620.
21. Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO Journal 1989, 8:757-764.
22. Wakasugi N., Tagaya Y., Wakasugi H., Mitsui A., Maeda M., Yodoi J., et al. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:8282-8286.
23. Yodoi J., Maeda M. Discovery of ATL: an odyssey in restrospect. International Journal of Hematology 2011, 94:423-428.
24. Nakamura H., Masutani H., Yodoi J. Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Seminars in Cell Biology 2006, 16:444-451.
25. Bertini R., Howard O.M., Dong H.F., Oppenheim J.J., Bizzarri C., Sergi R., et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. Journal of Experimental Medicine 1999, 189:1783-1789.
26. Nakamura H., De Rosa S.C., Yodoi J., Holmgren A., Ghezzi P., Herzenberg L.A., et al. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2688-2693.
27. Nakamura H., Herzenberg L.A., Bai J., Araya S., Kondo N., Nishinaka Y., et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:15143-15148.
28. Pekkari K., Holmgren A. Truncated thioredoxin: physiological functions and mechanism. Antioxidants and Redox Signalling 2004, 6:53-61.
29. Gil-Bea F., Akterin S., Persson T., Mateos L., Sandebring A., Avila-Carino J., et al. Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain. EMBO Molecular Medicine 2012, 4:1097-1111.
30. Rubartelli A., Bajetto A., Allavena G., Wollman E., Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. Journal of Biological Chemistry 1992, 267:24161-24164.
31. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine 2001, 31:1287-1312.
32. Kondo N., Ishii Y., Kwon Y.W., Tanito M., Horita H., Nishinaka Y., et al. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. Journal of Immunology 2004, 172:442-448.
33. Angelini G., Gardella S., Ardy M., Ciriolo M.R., Filomeni G., Di Trapani G., et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:1491-1496.
34. Nickel W. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. European Journal of Biochemistry 2003, 270:2109-2119.
35. Tanudji M., Hevi S., Chuck S.L. The nonclassic secretion of thioredoxin is not sensitive to redox state. American Journal of Physiology - Cell Physiology 2003, 284:C1272-C1279.
36. Keller M., Ruegg A., Werner S., Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-831.
37. Nakamura H., De Rosa S., Roederer M., Anderson M.T., Dubs J.G., Yodoi J., et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. International Immunology 1996, 8:603-611.
38. Miyazaki K., Noda N., Okada S., Hagiwara Y., Miyata M., Sakurabayashi I., et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 1998, 11:277-288.
39. Sumida Y., Nakashima T., Yoh T., Nakajima Y., Ishikawa H., Mitsuyoshi H., et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. Journal of Hepatology 2000, 33:616-622.
40. Sumida Y., Nakashima T., Yoh T., Furutani M., Hirohama A., Kakisaka Y., et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. Journal of Hepatology 2003, 38:32-38.
41. Koura T., Gon Y., Hashimoto S., Azuma A., Kudoh S., Fukuda Y., et al. Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation. Thorax 2000, 55:755-761.
42. Yamada Y., Nakamura H., Adachi T., Sannohe S., Oyamada H., Kayaba H., et al. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunology Letters 2003, 86:199-205.
43. Callister M.E., Burke-Gaffney A., Quinlan G.J., Nicholson A.G., Florio R., Nakamura H., et al. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006, 61:521-527.
44. Sakuma K., Nakamura H., Nakamura T., Hoshino Y., Ueda S., Ichikawa M., et al. Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease. Internal Medicine 2007, 46:1905-1909.
45. Okamoto M., Azuma K., Hoshino T., Imaoka H., Ikeda J., Kinoshita T., et al. Correlation of decreased survival and IL-18 in bone metastasis. Internal Medicine 2009, 48:763-773.
46. Takahashi K., Chin K., Nakamura H., Morita S., Sumi K., Oga T., et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxidants and Redox Signalling 2008, 10:715-726.
47. Maurice M.M., Nakamura H., Gringhuis S., Okamoto T., Yoshida S., Kullmann F., et al. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis and Rheumatism 1999, 42:2430-2439.
48. Yoshida S., Katoh T., Tetsuka T., Uno K., Matsui N., Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. Journal of Immunology 1999, 163:351-358.
49. Jikimoto T., Nishikubo Y., Koshiba M., Kanagawa S., Morinobu S., Morinobu A., et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Molecular Immunology 2002, 38:765-772.
50. Kurimoto C., Kawano S., Tsuji G., Hatachi S., Jikimoto T., Sugiyama D., et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjogren's syndrome. Journal of Rheumatology 2007, 34:2035-2043.
51. Nakamura H., Vaage J., Valen G., Padilla C.A., Bjornstedt M., Holmgren A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radical Biology and Medicine 1998, 24:1176-1186.
52. Kishimoto C., Shioji K., Nakamura H., Nakayama Y., Yodoi J., Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Japanese Circulation Journal 2001, 65:491-494.
53. Miyamoto S., Sakamoto T., Soejima H., Shimomura H., Kajiwara I., Kojima S., et al. Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. American Heart Journal 2003, 146:465-471.
54. Soejima H., Suefuji H., Miyamoto S., Kajiwaram I., Kojima S., Hokamaki J., et al. Increased plasma thioredoxin in patients with acute myocardial infarction. Clinical Cardiology 2003, 26:583-587.
55. Jekell A., Hossain A., Alehagen U., Dahlstrom U., Rosen A. Elevated circulating levels of thioredoxin and stress in chronic heart failure. European Journal of Heart Failure 2004, 6:883-890.
56. Hokamaki J., Kawano H., Soejima H., Miyamoto S., Kajiwara I., Kojima S., et al. Plasma thioredoxin levels in patients with unstable angina. International Journal of Cardiology 2005, 99:225-231.
57. Kakisaka Y., Nakashima T., Sumida Y., Yoh T., Nakamura H., Yodoi J., et al. Elevation of serum thioredoxin levels in patients with type 2 diabetes. Hormone and Metabolic Research 2002, 34:160-164.
58. Miyamoto S., Kawano H., Hokamaki J., Soejima H., Kojima S., Kudoh T., et al. Increased plasma levels of thioredoxin in patients with glucose intolerance. Internal Medicine 2005, 44:1127-1132.
59. Nakamura H., Bai J., Nishinaka Y., Ueda S., Sasada T., Ohshio G., et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detection and Prevention 2000, 24:53-60.
60. Ohashi S., Nishio A., Nakamura H., Kido M., Kiriya K., Asada M., et al. Clinical significance of serum thioredoxin 1 levels in patients with acute pancreatitis. Pancreas 2006, 32:264-270.
61. Abdiu A., Nakamura H., Sahaf B., Yodoi J., Holmgren A., Rosen A. Thioredoxin blood level increases after severe burn injury. Antioxidants and Redox Signalling 2000, 2:707-716.
62. Tamaki H., Nakamura H., Nishio A., Nakase H., Ueno S., Uza N., et al. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006, 131:1110-1121.
63. Hoshino Y., Shioji K., Nakamura H., Masutani H., Yodoi J. From oxygen sensing to heart failure: role of thioredoxin. Antioxidants and Redox Signalling 2007, 9:689-699.
64. Roederer M., Staal F.J., Osada H., Herzenberg L.A., Herzenberg L.A. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. International Immunology 1991, 3:933-937.
65. Nakamura T., Nakamura H., Hoshino T., Ueda S., Wada H., Yodoi J. Redox regulation of lung inflammation by thioredoxin. Antioxidants and Redox Signalling 2005, 7:60-71.
66. Miwa K., Kishimoto C., Nakamura H., Makita T., Ishii K., Okuda N., et al. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circulation Journal 2005, 69:291-294.
67. Nakamura H., Hoshino Y., Okuyama H., Matsuo Y., Yodoi J. Thioredoxin 1 delivery as new therapeutics. Advanced Drug Delivery Reviews 2009, 61:303-309.
68. Mitsui A., Hamuro J., Nakamura H., Kondo N., Hirabayashi Y., Ishizaki-Koizumi S., et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxidants and Redox Signalling 2002, 4:693-696.
69. Perez V.I., Cortez L.A., Lew C.M., Rodriguez M., Webb C.R., Van Remmen H., et al. Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2011, 66:1286-1299.
70. Matsushima S., Zablocki D., Sadoshima J. Application of recombinant thioredoxin1 for treatment of heart disease. Journal of Molecular and Cellular Cardiology 2011, 51:570-573.
71. Sato A., Hoshino Y., Hara T., Muro S., Nakamura H., Mishima M., et al. Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. Journal of Pharmacology and Experimental Therapeutics 2008, 325:380-388.
72. Tuder R.M., Petrache I. Pathogenesis of chronic obstructive pulmonary disease. Journal of Clinical Investigation 2012, 122:2749-2755.
73. Nakamura H., Tamura S., Watanabe I., Iwasaki T., Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunology Letters 2002, 82:165-170.
74. Yashiro M., Tsukahara H., Matsukawa A., Yamada M., Fujii Y., Nagaoka Y., et al. Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice. Critical Care Medicine 2013, 41:166-176.
75. Clark I.A. How TNF was recognized as a key mechanism of disease. Cytokine and Growth Factor Reviews 2007, 18:335-343.
76. Hofer S., Rosenhagen C., Nakamura H., Yodoi J., Bopp C., Zimmermann J.B., et al. Thioredoxin in human and experimental sepsis. Critical Care Medicine 2009, 37:2155-2159.
77. Leaver S.K., MacCallum N.S., Pingle V., Hacking M.B., Quinlan G.J., Evans T.W., et al. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Medicine 2010, 36:336-341.
78. Fukunaga A., Horikawa T., Ogura K., Taguchi K., Yu X., Funasaka Y., et al. Thioredoxin suppresses the contact hypersensitivity response by inhibiting leukocyte recruitment during the elicitation phase. Antioxidants and Redox Signalling 2009, 11:1227-1235.
79. Ono R., Masaki T., Dien S., Yu X., Fukunaga A., Yodoi J., et al. Suppressive effect of recombinant human thioredoxin on ultraviolet light-induced inflammation and apoptosis in murine skin. Journal of Dermatology 2012, 39:843-851.
80. Kim A.L., Labasi J.M., Zhu Y., Tang X., McClure K., Gabel C.A., et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. Journal of Investigative Dermatology 2005, 124:1318-1325.
81. Karin M., Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57:283-295.
82. Tan A., Nakamura H., Kondo N., Tanito M., Kwon Y.W., Ahsan M.K., et al. Thioredoxin-1 attenuates indomethacin-induced gastric mucosal injury in mice. Free Radical Research 2007, 41:861-869.
83. Nakajima A., Fukui T., Takahashi Y., Kishimoto M., Yamashina M., Nakayama S., et al. Attenuation of indomethacin-induced gastric mucosal injury by prophylactic administration of sake yeast-derived thioredoxin. Journal of Gastroenterology 2012, 47:978-987.
84. Inoue Y., Nomura W., Takeuchi Y., Ohdate T., Tamasu S., Kitaoka A., et al. Efficient extraction of thioreodoxin from Saccharomyces cerevisiae by ethanol. Applied and Environment Microbiology 2007, 73:1672-1675.
85. Taketani Y., Kinugasa K., Furukawa S., Nakamura H., Otsuki R., Yasuda H., et al. Yeast thioredoxin-enriched extracts for mitigating the allergenicity of foods. Bioscience, Biotechnology, and Biochemistry 2011, 75:1872-1879.
86. Daniell H., Kumar S., Dufourmantel N. Breakthrough in chloroplast genetic engineering of agronomically important crops. Trends in Biotechnology 2005, 23:238-245.
87. Lim S., Ashida H., Watanabe R., Inai K., Kim Y.S., Mukougawa K., et al. Production of biologically active human thioredoxin 1 protein in lettuce chloroplasts. Plant Molecular Biology 2011, 76:335-344.
88. Hara T., Kondo N., Nakamura H., Okuyama H., Mitsui A., Hoshino Y., et al. Cell-surface thioredoxin-1: possible involvement in thiol-mediated leukocyte-endothelial cell interaction through lipid rafts. Antioxidants and Redox Signalling 2007, 9:1427-1437.
89. Billiet L., Furman C., Larigauderie G., Copin C., Brand K., Fruchart J.C., et al. Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. Journal of Biological Chemistry 2005, 280:40310-40318.
90. Inomata Y., Tanihara H., Tanito M., Okuyama H., Hoshino Y., Kinumi T., et al. Suppression of choroidal neovascularization by thioredoxin-1 via interaction with complement factor H. Investigative Ophthalmology and Visual Science 2008, 49:5118-5125.
91. Kondo N., Ishii Y., Kwon Y.W., Tanito M., Sakakura-Nishiyama J., Mochizuki M., et al. Lipid raft-mediated uptake of cysteine-modified thioredoxin-1: apoptosis enhancement by inhibiting the endogenous thioredoxin-1. Antioxidants and Redox Signalling 2007, 9:1439-1448.
92. Watanabe R., Nakamura H., Masutani H., Yodoi J. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacological Therapy 2010, 127:261-270.
93. Jordan P.A., Gibbins J.M. Extracellular disulfide exchange and the regulation of cellular function. Antioxidants and Redox Signalling 2006, 8:312-324.
94. Hogg P.J. Disulfide bonds as switches for protein function. Trends in Biochemical Sciences 2003, 28:210-214.
95. Kaiser B.K., Yim D., Chow I.T., Gonzalez S., Dai Z., Mann H.H., et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007, 447:482-486.
96. Willems S.H., Tape C.J., Stanley P.L., Taylor N.A., Mills I.G., Neal D.E., et al. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochemical Journal 2010, 428:439-450.
97. Matthias L.J., Yam P.T., Jiang X.M., Vandegraaff N., Li P., Poumbourios P., et al. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nature Immunology 2002, 3:727-732.
98. Schwertassek U., Balmer Y., Gutscher M., Weingarten L., Preuss M., Engelhard J., et al. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO Journal 2007, 26:3086-3097.
99. Xu S.Z., Sukumar P., Zeng F., Li J., Jairaman A., English A., et al. TRPC channel activation by extracellular thioredoxin. Nature 2008, 451:69-72.
100. Soderberg A., Sahaf B., Rosen A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Research 2000, 60:2281-2289.